These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1134 related articles for article (PubMed ID: 15520202)

  • 21. Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II.
    Kalo E; Buganim Y; Shapira KE; Besserglick H; Goldfinger N; Weisz L; Stambolsky P; Henis YI; Rotter V
    Mol Cell Biol; 2007 Dec; 27(23):8228-42. PubMed ID: 17875924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An imbalance between Smad and MAPK pathways is responsible for TGF-beta tumor promoting effects in high-grade gliomas.
    Nickl-Jockschat T; Arslan F; Doerfelt A; Bogdahn U; Bosserhoff A; Hau P
    Int J Oncol; 2007 Feb; 30(2):499-507. PubMed ID: 17203233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
    Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
    Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo.
    Moore LD; Isayeva T; Siegal GP; Ponnazhagan S
    Clin Cancer Res; 2008 Aug; 14(15):4961-70. PubMed ID: 18676771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Growth inhibition due to complementation of transforming growth factor-beta receptor type II-defect by human chromosome 3 transfer in human colorectal carcinoma cells.
    Miyafuji Y; Zhong X; Uchida I; Koi M; Hemmi H
    J Cell Physiol; 2001 Jun; 187(3):356-64. PubMed ID: 11319759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential role of transforming growth factor beta1 in drug resistance of tumor cells.
    Stoika R; Yakymovych M; Souchelnytskyi S; Yakymovych I
    Acta Biochim Pol; 2003; 50(2):497-508. PubMed ID: 12833174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
    Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
    Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transforming growth factor-beta isoform and receptor expression in chondrosarcoma of bone.
    Masi L; Malentacchi C; Campanacci D; Franchi A
    Virchows Arch; 2002 May; 440(5):491-7. PubMed ID: 12021923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contextual effects of transforming growth factor beta on the tumorigenicity of human colon carcinoma cells.
    Ye SC; Foster JM; Li W; Liang J; Zborowska E; Venkateswarlu S; Gong J; Brattain MG; Willson JK
    Cancer Res; 1999 Sep; 59(18):4725-31. PubMed ID: 10493532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. alpha2HS-glycoprotein, an antagonist of transforming growth factor beta in vivo, inhibits intestinal tumor progression.
    Swallow CJ; Partridge EA; Macmillan JC; Tajirian T; DiGuglielmo GM; Hay K; Szweras M; Jahnen-Dechent W; Wrana JL; Redston M; Gallinger S; Dennis JW
    Cancer Res; 2004 Sep; 64(18):6402-9. PubMed ID: 15374947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transforming growth factor-beta 1 signaling contributes to Caco-2 cell growth inhibition induced by 1,25(OH)(2)D(3).
    Chen A; Davis BH; Sitrin MD; Brasitus TA; Bissonnette M
    Am J Physiol Gastrointest Liver Physiol; 2002 Oct; 283(4):G864-74. PubMed ID: 12223346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of extracellular signal-regulated kinase by TGF-beta1 via TbetaRII and Smad7 dependent mechanisms in human bronchial epithelial BEP2D cells.
    Huo YY; Hu YC; He XR; Wang Y; Song BQ; Zhou PK; Zhu MX; Li G; Wu DC
    Cell Biol Toxicol; 2007 Mar; 23(2):113-28. PubMed ID: 17096210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aryl hydrocarbon receptor inhibition downregulates the TGF-beta/Smad pathway in human glioblastoma cells.
    Gramatzki D; Pantazis G; Schittenhelm J; Tabatabai G; Köhle C; Wick W; Schwarz M; Weller M; Tritschler I
    Oncogene; 2009 Jul; 28(28):2593-605. PubMed ID: 19465936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats.
    Laping NJ; Everitt JI; Frazier KS; Burgert M; Portis MJ; Cadacio C; Gold LI; Walker CL
    Clin Cancer Res; 2007 May; 13(10):3087-99. PubMed ID: 17505012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines.
    Tian F; Byfield SD; Parks WT; Stuelten CH; Nemani D; Zhang YE; Roberts AB
    Cancer Res; 2004 Jul; 64(13):4523-30. PubMed ID: 15231662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ALK5 promotes tumor angiogenesis by upregulating matrix metalloproteinase-9 in tumor cells.
    Safina A; Vandette E; Bakin AV
    Oncogene; 2007 Apr; 26(17):2407-22. PubMed ID: 17072348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis.
    Grygielko ET; Martin WM; Tweed C; Thornton P; Harling J; Brooks DP; Laping NJ
    J Pharmacol Exp Ther; 2005 Jun; 313(3):943-51. PubMed ID: 15769863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
    Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
    Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A kunitz-type protease inhibitor bikunin disrupts ligand-induced oligomerization of receptors for transforming growth factor (TGF)-beta and subsequently suppresses TGF-beta signalings.
    Yagyu T; Kobayashi H; Wakahara K; Matsuzaki H; Kondo T; Kurita N; Sekino H; Inagaki K; Suzuki M; Kanayama N; Terao T
    FEBS Lett; 2004 Oct; 576(3):408-16. PubMed ID: 15498571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TGF-beta superfamily enhances the antigen-induced IFN-gamma production by effector/memory CD8+ T cells.
    Takai S; Tokuda H; Matsushima-Nishiwaki R; Saio M; Takami T; Kozawa O
    Int J Mol Med; 2010 Jan; 25(1):105-11. PubMed ID: 19956908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.